Infinity announces Phase 2 clinical trial results of IPI-504 for NSCLC

[News]

Infinity Pharmaceuticals, Inc. today reported the results from its Phase 2 clinical trial of IPI-504, the company's i.v.-administered Hsp90 chaperone inhibitor, in patients with advanced non-small cell lung cancer (NSCLC). Data reported show that IPI-504 demonstrated clinical activity in patients with NSCLC, in particular among patients with oncogenic anaplastic lymphoma kinase (ALK) gene rearrangements.

More... (http://www.news-medical.net/news/20100604/Infinity-announces-Phase-2-clinical-trial-results-of-IPI-504-for-NSCLC.aspx)